Ansuvimab
Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication for the treatment of Zaire ebolavirus (Ebolavirus) infection.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Zaire ebolavirus |
| Clinical data | |
| Trade names | Ebanga |
| Other names | Ansuvimab-zykl, mAb114 |
| License data | |
| Routes of administration | Intravenous |
| Drug class | Monoclonal antibody |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6368H9924N1724O1994S44 |
| Molar mass | 143950.15 g·mol−1 |
The most common symptoms include fever, tachycardia (fast heart rate), diarrhea, vomiting, hypotension (low blood pressure), tachypnea (fast breathing) and chills; however, these are also common symptoms of Ebolavirus infection.
Ansuvimab was approved for medical use in the United States in December 2020. It is on the World Health Organization's List of Essential Medicines.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.